Clinical trial
Hypoxia Imaging With the Novel Radiopharmaceutical 18F Fluoroazomycin Arabinoside (FAZA)- Prognostic Impact in Cervical Cancer
NCT00388687 is registered in ClinicalTrials.gov with Medical University of Vienna as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Hypoxia Imaging With the Novel Radiopharmaceutical 18F Fluoroazomycin Arabinoside (FAZA)- Prognostic Impact in Cervical Cancer
- Lead sponsor
- Medical University of Vienna
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- July 31, 2006
- Completion date
- July 31, 2007
- Enrollment
- 25
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.